guest :: login
DKFZ
    Search   Submit  
Personalize
  • Your alerts
  • Your baskets
  • Your searches
  Help    
Home > Publications database > Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial. > Access to Fulltext
  • Information
  • Files
 
 
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial. - DKFZ-2024-02612
 
Main document file(s):
      mai-et-al-2024-isatuximab-lenalidomide-bortezomib-and-dexamethasone-induction-therapy-for-transplant-eligible-newly
    version 1
    mai-et-al-2024-isatuximab-lenalidomide-bortezomib-and-dexamethasone-induction-therapy-for-transplant-eligible-newly.pdf [1.4 MB] 24 Nov 2025, 11:03 OpenAccess
    mai-et-al-2024-isatuximab-lenalidomide-bortezomib-and-dexamethasone-induction-therapy-for-transplant-eligible-newly.pdf (pdfa) [1.39 MB] 24 Nov 2025, 11:03 OpenAccess
Similar records

DKFZ :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.7 | join2_v2601a
Maintained by zb.invenio@dkfz-heidelberg.de

Impressum | Data Privacy Policy